Poor
Needs Revision
Patient Risk:
Moderate
Summary
The claims include a few points consistent with the label, but give numerous unsupported testing schedules, risk thresholds, and medication actions. The label instead directs testing as clinically indicated and says to consider withdrawal if ALT or AST elevations of at least 3 × ULN persist.
Category Scores
Accurate Statements
Ezetimibe adds a small incremental transaminitis risk when combined with a statin.
The label reports consecutive transaminase elevations of at least 3 × ULN in 1.3% with ZETIA plus a statin versus 0.4% with a statin alone. The direction of the difference is supported, but the label does not characterize it as small.
Unsupported Statements
Baseline testing and scheduled repeat liver-function tests are recommended at 1–3 months, 3 months, or 3–6 months, including after starting treatment, dose changes, or for high-risk patients.
The label does not specify baseline testing or these monitoring schedules; it directs liver-enzyme testing as clinically indicated.
Specific symptoms or risk factors require liver tests, and testing can be omitted annually or for the duration of treatment if they are absent.
The label does not specify symptom-based or risk-factor-based testing criteria, nor does it describe annual or duration-based testing practices.
AST or ALT elevations of 2–5 × ULN warrant holding ezetimibe, rechecking in 1–2 weeks, or considering alternative lipid therapy; elevations greater than 5 × ULN warrant discontinuation.
The label does not give these thresholds or actions. It says to consider withdrawal if ALT or AST elevations of at least 3 × ULN persist.
For elevations greater than 5 × ULN during combination treatment, the statin may also be discontinued.
The label does not provide this threshold-based instruction and directs readers to the statin’s prescribing information for its risks.
Statins are the main driver of transaminitis risk when combined with ezetimibe.
The label provides rates for combination treatment and statin treatment alone but does not attribute the risk to either drug as the main driver.
Ezetimibe monotherapy has no evidence of significant hepatotoxicity, or routine liver-function monitoring is not recommended for monotherapy.
The label reports serum transaminase increases and directs testing as clinically indicated; it does not make these monotherapy-specific conclusions.
Contradictions
Important Omissions
The label says to consider withdrawal of ZETIA if ALT or AST elevations of at least 3 × ULN persist.
Importance:
High
The label states that ZETIA is not recommended in patients with moderate to severe hepatic impairment (Child-Pugh B or C).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported testing schedules and enzyme thresholds could lead to unnecessary testing or medication interruption, while the claims omit the label’s persistent ≥3 × ULN withdrawal consideration and restriction for moderate to severe hepatic impairment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
The claims present multiple monitoring schedules and enzyme-based medication actions that are not specified in the supplied label.
Suggested Improvement
Align the monitoring advice with the label: perform liver-enzyme testing as clinically indicated and consider withdrawal if ALT or AST elevations of at least 3 × ULN persist. Include the label’s recommendation against use in moderate to severe hepatic impairment.